Research programme: immunotherapies and vaccines - Heat Biologics

Drug Profile

Research programme: immunotherapies and vaccines - Heat Biologics

Alternative Names: Anti-TLIA - Heat Biologics; Anti-TNFRSF25 - Heat Biologics; Fc-OX40L; HS 310 - Heat Biologics; HS-120; HS-210; HS-310; HS-HCV; HS-HIV; HS-HIV/SIV; HS-HIV1; HS-O1; HS-P1; IN-A1; Inhibicor; Medicor

Latest Information Update: 16 Nov 2016

Price : $50

At a glance

  • Originator Heat Biologics
  • Developer Heat Biologics; OncoSec Medical
  • Class AIDS vaccines; Antibodies; Cancer vaccines; Cell therapies; Heat shock proteins; Immunoglobulin fusion proteins; Tumour cell vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants; Tumour necrosis factor ligand superfamily member 15 inhibitors; Tumour necrosis factor member 25 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours
  • Suspended Hepatitis C
  • Discontinued Asthma; Autoimmune disorders; HIV-1 infections; Transplant rejection

Most Recent Events

  • 14 Nov 2016 Pharmacodynamics data from a preclinical trial in Cancer released by Heat Biologics
  • 25 Apr 2016 Discontinued - Preclinical for HIV-1 infections in USA (Parenteral) (Heat Biologics' pipeline April- 2016)
  • 18 Apr 2016 Preclinical trials in Solid tumours in USA (Parenteral) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top